What is polycythemia in a newborn?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Neonatal Polycythemia: Definition, Causes, and Management

Neonatal polycythemia is defined as a venous hematocrit above 65%, which leads to hyperviscosity of blood and can cause symptoms of hypoperfusion affecting multiple organ systems. 1

Definition and Pathophysiology

Polycythemia in newborns refers to an abnormally high concentration of red blood cells in the blood, specifically:

  • Venous hematocrit ≥65% 1, 2
  • Relationship between hematocrit and blood viscosity is linear until 65%, then becomes exponential 1
  • Hematocrit in newborns naturally peaks at 2 hours of age and gradually decreases thereafter 1

The increased blood viscosity from polycythemia leads to decreased blood flow to various organs, potentially causing tissue hypoperfusion and organ dysfunction 3.

Types and Causes

Neonatal polycythemia can be classified into two main categories:

  1. Active Polycythemia - Excess production of red blood cells 4

    • Chronic intrauterine hypoxia
    • Placental insufficiency
    • Genetic disorders
  2. Passive Polycythemia - Increase in fetal blood volume 4

    • Delayed cord clamping
    • Twin-to-twin transfusion syndrome (TAPS)
    • Maternal-fetal transfusion

High-Risk Groups

Certain newborns are at increased risk and should undergo screening at 2,12, and 24 hours of age 1:

  • Small for gestational age (SGA) infants
  • Infants of diabetic mothers (IDM)
  • Multiple births (particularly monochorionic twins)
  • Infants with cyanotic congenital heart disease 5

Clinical Manifestations

Polycythemia can affect multiple organ systems due to hyperviscosity and reduced blood flow:

  • Neurological: Lethargy, irritability, seizures, jitteriness
  • Cardiovascular: Decreased cardiac output, reduced cerebral blood flow 3, 6
  • Pulmonary: Decreased pulmonary blood flow, respiratory distress 3
  • Renal: Reduced renal plasma flow, decreased glomerular filtration rate 3
  • Gastrointestinal: Feeding intolerance, necrotizing enterocolitis
  • Hematological: Thrombocytopenia, hyperbilirubinemia
  • Metabolic: Hypoglycemia

Diagnosis

  • Venous hematocrit ≥65% is diagnostic 1, 2
  • Capillary samples may be falsely elevated and should be confirmed with venous sampling
  • Screening recommended for high-risk infants at 2,12, and 24 hours of age 1
  • In twin pregnancies, middle cerebral artery Doppler peak systolic velocity can help diagnose twin anemia-polycythemia sequence (TAPS) prenatally 5

Management

Management depends on whether the infant is symptomatic:

Asymptomatic Polycythemia:

  • Supportive care with close monitoring
  • Adequate hydration
  • Current evidence does not support partial exchange transfusion (PET) for asymptomatic infants 2

Symptomatic Polycythemia:

  • Partial exchange transfusion (PET) is the definitive treatment for symptomatic infants 4
    • Reduces hematocrit and blood viscosity
    • Improves pulmonary blood flow and renal function 3
    • Crystalloids are as effective as colloids for PET and have fewer risks 2

Prognosis and Long-term Outcomes

  • Short-term improvements in organ function can be seen after treatment of symptomatic polycythemia
  • Long-term neurodevelopmental outcomes are not clearly improved by PET 2
  • Neurological abnormalities may be due to primary hypoxic events rather than reduced cerebral blood flow 3

Important Considerations

  • Cerebral blood flow reduction in polycythemia appears to be a physiologic response to increased arterial oxygen content rather than a direct result of hyperviscosity 6
  • In twin pregnancies with TAPS, the recipient twin may develop polycythemia and hyperviscosity, potentially leading to cerebral lesions, skin necrosis, and limb ischemia 5
  • Polycythemia in cyanotic congenital heart disease occurs as a compensatory mechanism to increase tissue oxygenation in response to chronic hypoxemia 5

Screening Recommendations

For high-risk infants (SGA, IDM, multiple births), screening should be performed at:

  • 2 hours of age
  • 12 hours of age
  • 24 hours of age 1

Early identification and appropriate management of neonatal polycythemia can help prevent complications and improve outcomes.

References

Research

Management of polycythemia in neonates.

Indian journal of pediatrics, 2010

Research

Neonatal polycythemia and hyperviscosity.

Seminars in fetal & neonatal medicine, 2008

Research

Polycythemia and hyperviscosity in the newborn.

Seminars in thrombosis and hemostasis, 2003

Research

Polycythemia in the newborn.

MCN. The American journal of maternal child nursing, 2003

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.